Recently, the National High-tech Enterprise Certification Management Office officially announced the latest list of recognized enterprises. Optoseeker Biotech has successfully earned the prestigious "National High-Tech Enterprise" designation. This certification is a testament to the company’s core technological breakthroughs in high-end life science instruments, its continuous R&D innovation, and its robust market potential. This national-level recognition serves as an authoritative endorsement of the company’s R&D capabilities and achievements in technology transfer. It marks a decisive step forward for Optoseeker Biotech in the localization of high-end life science instruments, officially elevating the company into the ranks of national high-tech leaders.
Authoritative Recognition: Highlighting Core Strength
The "National High-Tech Enterprise" certification is one of the most coveted honors in China’s technology sector. The evaluation process is exceptionally rigorous, assessing companies across four critical dimensions: core intellectual property (IP), technology transfer capabilities, R&D management excellence, and corporate growth potential.
Since its inception, Optoseeker Biotech has placed R&D at the heart of its development strategy. Focusing on cutting-edge fields such as optoelectronic tweezers, microfluidics, antibody discovery, cell therapy, and gene editing, the company has built an end-to-end, self-controllable platform. Powered by its proprietary OptoBot® series—a high-throughput single-cell optofluidic sorter—the platform covers the entire workflow from "screening and sequencing" to "data analysis." This innovation addresses critical pain points for biopharmaceutical companies, significantly shortening antibody screening cycles and reducing R&D costs for cell and gene therapies. Today, many of Optoseeker Biotech’s innovations have achieved successful market application, winning widespread acclaim for their stable performance and professional service.
Furthermore, the high-end life science instrument industry is a high-barrier, long-cycle, and capital-intensive "hard tech" sector that has long been dominated by international giants. Optoseeker Biotech’s products meet international high-end standards, successfully filling technical gaps in the domestic market. By achieving full-chain control over hardware, software, and consumables, the company is breaking foreign monopolies and driving domestic substitution—a core value highly prioritized and supported by the National High-Tech Enterprise certification.
Innovation-Driven: Building a Foundation for Growth
Optoseeker Biotech remains market-oriented, staying ahead of industry trends and continuously optimizing its product structure to enhance competitiveness. As of today, the company holds 9 authorized patents with another 38 patents pending. Many of its technologies lead the industry, providing a solid foundation for rapid corporate scaling.
This certification will further bolster the company’s brand influence and market credibility. It will provide a strategic advantage in market expansion, R&D investment, policy support, and talent acquisition, enabling Optoseeker Biotech to seize opportunities in a competitive landscape and accelerate the commercialization of scientific achievements.
Seizing the Momentum: A New Chapter of Excellence
The title of "National High-Tech Enterprise" is not only an honor but also a responsibility. Moving forward, Optoseeker Biotech will leverage this milestone to focus on the iterative upgrade of core products and breakthroughs in key technologies. We will continue to strengthen our innovation foundation, increase R&D investment, and accelerate the industrialization of research findings.
Optoseeker Biotech is committed to operating under the highest standards of a National High-Tech Enterprise. We will continue to lead by example, fulfill our social responsibilities, and remain deeply rooted in the field of high-end life science instruments. Through relentless innovation, we aim to drive domestic substitution and inject new momentum into the high-quality development of China’s biotechnology industry.
